Division of GtreeBNT Co. Ltd.
Latest From ReGenTree LLC
Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.
The FDA is requiring an additional RGN-259 Phase III trial to further show efficacy in both signs and symptoms of dry eye in a larger patient population.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
ReGenTree has reported mixed results in its second pivotal Phase III trial of RGN-259 indicating that the therapy is most effective in patients with severe dry eye. The results raise some doubts about the treatment’s potential approval for the general dry eye population.
- Large Molecule
- Therapeutic Areas
- G-treeBNT-RegeneRx joint venture
- North America
- Parent & Subsidiaries
- GtreeBNT Co. Ltd.
- Senior Management
- Contact Info
Phone: (609) 734-4328
116 Village Blvd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.